276 related articles for article (PubMed ID: 12078896)
1. Fertility after treatment for Hodgkin's disease.
Blumenfeld Z; Dann E; Avivi I; Epelbaum R; Rowe JM
Ann Oncol; 2002; 13 Suppl 1():138-47. PubMed ID: 12078896
[TBL] [Abstract][Full Text] [Related]
2. Ovarian rescue/protection from chemotherapeutic agents.
Blumenfeld Z
J Soc Gynecol Investig; 2001; 8(1 Suppl Proceedings):S60-4. PubMed ID: 11223377
[TBL] [Abstract][Full Text] [Related]
3. Preservation of fertility and ovarian function and minimalization of chemotherapy associated gonadotoxicity and premature ovarian failure: the role of inhibin-A and -B as markers.
Blumenfeld Z
Mol Cell Endocrinol; 2002 Feb; 187(1-2):93-105. PubMed ID: 11988316
[TBL] [Abstract][Full Text] [Related]
4. Inhibin A concentrations in the sera of young women during and after chemotherapy for lymphoma: correlation with ovarian toxicity.
Blumenfeld Z; Ritter M; Shen-Orr Z; Shariki K; Ben-Shahar M; Haim N
Am J Reprod Immunol; 1998 Jan; 39(1):33-40. PubMed ID: 9458932
[TBL] [Abstract][Full Text] [Related]
5. Preservation of fertility and ovarian function and minimizing chemotherapy-induced gonadotoxicity in young women.
Blumenfeld Z; Avivi I; Ritter M; Rowe JM
J Soc Gynecol Investig; 1999; 6(5):229-39. PubMed ID: 10554760
[TBL] [Abstract][Full Text] [Related]
6. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy.
Blumenfeld Z; Avivi I; Linn S; Epelbaum R; Ben-Shahar M; Haim N
Hum Reprod; 1996 Aug; 11(8):1620-6. PubMed ID: 8921104
[TBL] [Abstract][Full Text] [Related]
7. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy.
Blumenfeld Z; Shapiro D; Shteinberg M; Avivi I; Nahir M
Lupus; 2000; 9(6):401-5. PubMed ID: 10981642
[TBL] [Abstract][Full Text] [Related]
8. Gynaecologic concerns for young women exposed to gonadotoxic chemotherapy.
Blumenfeld Z
Curr Opin Obstet Gynecol; 2003 Oct; 15(5):359-70. PubMed ID: 14501238
[TBL] [Abstract][Full Text] [Related]
9. Prevention of gonadal damage during cytotoxic therapy.
Blumenfeld Z; Haim N
Ann Med; 1997 Jun; 29(3):199-206. PubMed ID: 9240625
[TBL] [Abstract][Full Text] [Related]
10. Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma.
Blumenfeld Z; Avivi I; Eckman A; Epelbaum R; Rowe JM; Dann EJ
Fertil Steril; 2008 Jan; 89(1):166-73. PubMed ID: 17601603
[TBL] [Abstract][Full Text] [Related]
11. Gender difference: fertility preservation in young women but not in men exposed to gonadotoxic chemotherapy.
Blumenfeld Z
Minerva Endocrinol; 2007 Mar; 32(1):23-34. PubMed ID: 17353864
[TBL] [Abstract][Full Text] [Related]
12. Assessment of ovarian reserve following ovarian tissue banking and/or GnRH-a co-treatment prior to chemotherapy in patients with Hodgkin's disease.
Azem F; Samara N; Cohen T; Ben-Yosef D; Almog B; Lessing JB; Goor O; Amit A
J Assist Reprod Genet; 2008; 25(11-12):535-8. PubMed ID: 19015974
[TBL] [Abstract][Full Text] [Related]
13. Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD).
Giuseppe L; Attilio G; Edoardo DN; Loredana G; Cristina L; Vincenzo L
Hematology; 2007 Apr; 12(2):141-7. PubMed ID: 17454195
[TBL] [Abstract][Full Text] [Related]
14. Gonadotropin-releasing hormone agonist may minimize premature ovarian failure in young women undergoing autologous stem cell transplantation.
Blumenfeld Z; Patel B; Leiba R; Zuckerman T
Fertil Steril; 2012 Nov; 98(5):1266-70.e1. PubMed ID: 22935556
[TBL] [Abstract][Full Text] [Related]
15. Preservation of fertility and ovarian function and minimization of chemotherapy-induced gonadotoxicity in young women by GnRH-a.
Blumenfeld Z; Eckman A
J Natl Cancer Inst Monogr; 2005; (34):40-3. PubMed ID: 15784821
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer.
Munster PN; Moore AP; Ismail-Khan R; Cox CE; Lacevic M; Gross-King M; Xu P; Carter WB; Minton SE
J Clin Oncol; 2012 Feb; 30(5):533-8. PubMed ID: 22231041
[TBL] [Abstract][Full Text] [Related]
17. Comment on the symposium article "Fertility after treatment for Hodgkin's disease", by Z. Blumenfeld, E. Dann, I. Avivi et al. (Ann Oncol 2002; 13 Suppl 1: 138-147).
Bohlmann MK; von Wolff M; Strowitzki T
Ann Oncol; 2003 Mar; 14(3):499; author reply 499-500. PubMed ID: 12598361
[No Abstract] [Full Text] [Related]
18. Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a prospective randomized trial.
Demeestere I; Brice P; Peccatori FA; Kentos A; Gaillard I; Zachee P; Casasnovas RO; Van Den Neste E; Dechene J; De Maertelaer V; Bron D; Englert Y
J Clin Oncol; 2013 Mar; 31(7):903-9. PubMed ID: 23129737
[TBL] [Abstract][Full Text] [Related]
19. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries.
Blumenfeld Z
Oncologist; 2007 Sep; 12(9):1044-54. PubMed ID: 17914074
[TBL] [Abstract][Full Text] [Related]
20. Gonadal protection by a gonadotropin-releasing hormone agonist depot in young women with Hodgkin's disease undergoing chemotherapy.
Franke HR; Smit WM; Vermes I
Gynecol Endocrinol; 2005 May; 20(5):274-8. PubMed ID: 16019373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
